Now Available to Order from Par Sterile Products, LLC

**Vasostrict® (Vasopressin Injection, USP)**

The First & Only FDA-Approved Vasopressin Injection, USP

---

**Refrigeration is required ¹**

- Quality You Can Trust
- Supply to Meet Demand
- Latex-Free

---

For customer service inquiries, please call: 800-828-9393, option 5, option 2
For medical information inquiries, please call: 800-828-9393, option 2; eFax: 201-829-9222; Email: druginfo@parpharm.com

---

<table>
<thead>
<tr>
<th>NDC</th>
<th>Name</th>
<th>Strength</th>
<th>Fill Volume</th>
<th>ABC Order #</th>
<th>Cardinal Order #</th>
<th>McKesson Order #</th>
<th>M&amp;D Order #</th>
</tr>
</thead>
<tbody>
<tr>
<td>42023-164-25</td>
<td>Vasostrict® (Vasopressin Injection, USP)</td>
<td>20 units/mL</td>
<td>1 mL MDV</td>
<td>10145143</td>
<td>5033428</td>
<td>3424330</td>
<td>913442</td>
</tr>
</tbody>
</table>

1. Vials may be held up to 12 months upon removal from refrigeration to room temperature storage conditions (20°C to 25°C [68°F to 77°F], USP Controlled Room Temperature), anytime within the labeled shelf life.

Please see reverse for Full Prescribing Information

© 2015  PSPB01 1115
1. INDICATIONS AND USAGE

Vasostrict® is indicated to increase blood pressure in adults with vasodilatory shock (e.g., postcardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines. (1)

2. DOSAGE AND ADMINISTRATION

2.1 Preparation of Diluted Solutions

Dilute Vasostrict® in normal saline (0.9% sodium chloride) or 5% dextrose in water (D5W) to either 0.1 units/mL or 1 unit/mL for intravenous administration. Discard unused diluted solution after 18 hours at room temperature or 24 hours after refrigeration. (2.1)

2.2 Administration

Adverse reactions associated with the use of vasopressin are well characterized. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.

3. DRUG INTERACTIONS

Use with caution in patients on other vasoactive agents or aminoglycosides. (7.2)

7.5 Drugs Suspected of Causing SIADH

Use with caution in patients with pre-existing diabetes insipidus or on agents that cause hyperglycemia. (7.6)

8.1 Pregnancy

There are no adequate or well-controlled studies of Vasostrict® in pregnant women. Use Vasostrict® in pregnancy only if the potential benefit justifies the potential risk to the fetus. (8.1)

8.2 Lactation

It is not known whether vasopressin is present in human milk. However, because many drugs are excreted in human milk, breastfeed infants of their mothers if important and the drug is required in the therapy. (8.2)

9.2 Vasostrict® is contraindicated in patients with known allergy or hypersensitivity to L-arginine vasopressin or chlorobutanol. (4)

9.3 Use in Patients with Renal Failure

When administered to a pregnant woman or can affect reproduction capacity. During the first trimester of pregnancy the placental barrier is relatively impermeable. Therefore, the drug reaches the fetus at a lower concentration. (12.1)